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Poster Session I S313BMD as a surrogate marker of bone health in children/ adoles-
cents, the prevalence of compromised bone health determined by
DXA correlated with symptoms in our cohort demonstrated the
value of this objective measure. There is need to systematize
BMD evaluations to optimize the opportunities of restoring
bone mineral loss during the growing years of pediatric HCT
recipients.
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Objectives:To systematically prioritize research gaps in the areas of
HSCT for pediatric malignant solid tumors, inheritedmetabolic dis-
ease, and autoimmune disease. In addition to develop a list of re-
search questions to address the prioritized gaps identified in
a comparative effectiveness review of HSCT for pediatrics.
Methods: Central to the methodology of this report was the use of
key informants to identify and prioritize evidence gaps. We elicited
expert opinion from a group of nine clinical experts, to ensure clin-
ical relevance, a group of patient advocates, and a payer. Through an
iterative process, the key informants identified and prioritized re-
search gaps. They then generated and prioritized a list of potential
research studies to address these gaps. For the assessment of study
designs, we evaluated the appropriateness of a randomized trial,
a nonrandomized trial, and a cohort design.
Results: Seven research gaps were identified through a combina-
tion of the HSCT CER and conversations with key informants.
The patient advocates provided a valuable, unique perspective
that resulted in the identification of two additional research gaps
and associated research questions. With the patient advocates we
intended solely to focus on discussing outcomes. However, the ad-
vocates broadened the discussion which in the end coalesced
around issues central to the concept of a patient-centered medical
home, which could provide the long-term clinical and pharmacy
support to help a family from diagnosis to the transition from
the treatment center back to their community and then through
long-term follow-up. The final prioritized list of gaps is cross-cut-
ting in that each gap applies to more than one indication for
HSCT. These appear with their associated key questions, in order
of priority in Table 1.
Conclusions: In addition to the prioritized gaps and key questions
highlighted by this work, the role of patient advocates, in this case
mothers of transplant recipients, was essential to the identification
of research gaps along the entire continuum of care from diagnosis
to long-term follow-up.Table 1. RESULTS: Prioritized gaps and key questions
Prioritized Gap
1. Mitigation of long term adverse effects by changes in regimen, including
reduced intensity approaches, and changes in subsequent medical or
psychosocial intervention.
2. Role of novel therapies for HSCT in altering short-term adverse effects
and the long-term effects of these therapies. Such approaches include:
3. Impact on outcomes of a ‘‘family-centered’’ approach to transplantation.
Advocates of children who have undergone HSCT defined such an
approach as including: emotional and psychosocial counseling for the
family with a special attention on donor and non-donor siblings,
information to share with caregivers and peers, and, provision of tools
rather than only a large amount of information for navigating the
complexities of the medical system and medication management.
4. Effectiveness of survivorship planning on long term, comprehensive
follow-up and outcomes.292
SAFETY ANALYSIS OF UPPER GASTROINTESTINAL TRACT ENDOSCOPY IN
CHILDREN AND ADOLESCENTS AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION: A FIVE-YEAR, SINGLE-INSTITUTION
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Indroduction:Upper gastrointestinal tract (GIT) endoscopy is a fre-
quent procedure after allogeneic HSCT, mainly in the context of
suspected GvHD.Here, we report our analysis of upper GIT endos-
copy in a pediatric, allogeneic HSCT cohort over a period of five
years with a special focus on safety aspects.
Patients and Results: From 2007 to 2011, 24 of 86 (28%) pediatric
allogeneic HSCT patients had upper GIT endoscopy for various
reasons between days +2 and +1079 with a median of day +72. The
total number of procedures was 57 with 14 patients having multiple
procedures (2-7). The 15 males and 9 females were between 2 to 22
years old (mean 10.2, median 9 years) at the time of their first proce-
dure. Their diagnoses were ALL (11), Fanconi anemia (5), MDS (3),
AML (3), Dyskeratosis congenita (1) and Shwachman-Diamond syn-
drome (1). Transplants were from MSD in 5, from MUD and
MMUD in 15 and 4 patients, respectively. The mean platelet count
before the procedure was 148000/ml (26000-347000), mean PT
100% (55-130), mean PTT 30sec (23-42) and mean fibrinogen
384mg/dl (113-758). The procedures were primarily performed by
pediatric gastroenterology or pediatric surgery and only rarely by
adult gastroenterology. The safety analysis included the need of pro-
cedure-related initiation or prolongation of mechanical ventilation,
blood pressure support, need of transfer to the ICU, GIT wall per-
foration, occurrence of GIT hemorrhage, and any clinically relevant
disturbance of GIT motility. Altogether, procedural adverse events
were noted in 1 of 57 procedures (1.8%): A 3-year-old girl had to
be transferred to the pediatric ICU on the day of her procedure
for life-threatening intestinal hemorrhage at the site of a duodenal
biopsy. One day later she also developed a complete duodenal ob-
struction caused by an intramural duodenal hematoma. Platelet
count and coagulation parameters were not different from other pa-
tients in this analysis. Over a period of 4 weeks, the obstruction re-
solved. Possible risk factors in this patient were treatment with
defibrotide and disseminated adenovirus disease. All other patients
in our analysis had an unremarkable post-procedural course.
Conclusions: Despite of the existence of several potential risk fac-
tors, upper GIT endoscopy in children and adolescents after alloge-
neic HSCT usually is a safe procedure. Intestinal hemorrhage and
duodenal wall hematoma with mechanical obstruction is an infre-
quent, but potentially life-threatening adverse event.Key Questions
1.1 Can intense psychological support of patient, parents and siblings prevent
development of post-transplant psychological disorders (including PTSD,
depression, anxiety, other adverse psychological outcomes) in ‘‘surviving’’
and ‘‘non-surviving’’ family members?
2.1 For pediatric patients receiving a transplant due to cancer: Are there
interventions that maymitigate immediate and late adverse effects without
interfering with the immunotherapeutic effects? 2.2 For pediatric patients
receiving a transplant for non-cancerous indications: Are there
interventions that maymitigate immediate and late adverse effects without
interfering with the establishment and maintenance of chimerism?
3.1 What approached to integrated care, from diagnosis forward, have the
greatest impact in family functioning and overall health and well-being for
families faced with pediatric transplant?
4.1 Does survivorship planning enhance compliance with long-term follow-
up? 4.2What are the comparative outcomes for those that participate in
long-term survivorship follow-up versus those who do not?
